Effect of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Patient-Reported Vitality and Mental Health in Patients with Relapsing Multiple Sclerosis in a Phase 2 Trial

Authors
Category Primary study
ConferenceMultiple Sclerosis and Related Disorders
Year 2023
This article has no abstract
Epistemonikos ID: b1506ec032841e10a4695f52eb52fb58aa26634e
First added on: Feb 18, 2025